Skip to main content
MarketStoryBook
All storiesBIIB in “The Patent Cliff Sparks a Biotech Land Grab”BIIB in storiesBIIB stock

BIIB in “The Patent Cliff Sparks a Biotech Land Grab”

Biogen Inc.

Bear sideFadingExposure: not rated yet

Erosion in mature neurological franchises and uneven internal pipeline execution leave Biogen under pressure to license or acquire new growth assets.

BIIB impact map — “The Patent Cliff Sparks a Biotech Land Grab”

How this story travels from the headline to BIIB’s own business — positive, negative or mixed, direct or indirect, the mechanism, and how strong the exposure is.

Loading BIIB impact map…

Price history, marked with story events

Aug 31, 2026 – Oct 19, 2026 · 32 sessions

Prices updated during market hours · refreshed about every 30 minutes while the market is open · delayed data, not for trading decisions

Numbered markers tie price moves to earnings, trial or study results, management comments and analyst or demand data. Loading events…

Full story

The Patent Cliff Sparks a Biotech Land Grab

Large drugmakers facing revenue holes must buy scarce pipelines, turning clinical validation into strategic currency.

BEAR side — Erosion in mature neurological franchises and uneven internal pipeline execution leave Biogen under pressure to license or acquire new growth assets.

Read the full The Patent Cliff Sparks a Biotech Land Grab story

Bull side

0 stories

No bull-side stories for BIIB yet.

Bear side

2 stories
  • America Imports the World's Drug Prices

    BIIB in “America Imports the World's Drug Prices”

    StableExposure: not rated yet

    US reference pricing puts global blockbuster economics—and not just American list prices—under pressure.

    Biogen relies on premium-priced patented neurology medicines whose lifetime economics could weaken if US reimbursement is benchmarked against lower overseas prices.

  • BIIB in “The Patent Cliff Sparks a Biotech Land Grab”

    FadingExposure: not rated yet
    Viewing

    Large drugmakers facing revenue holes must buy scarce pipelines, turning clinical validation into strategic currency.

    Erosion in mature neurological franchises and uneven internal pipeline execution leave Biogen under pressure to license or acquire new growth assets.